Parexel and Palantir Expand Collaboration to Leverage AI Capabilities in Clinical Trials


Under new multi-year strategic partnership, Parexel will utilize Palantir’s artificial intelligence platform.

© lidiia - © lidiia -

Image Credit: © lidiia -

Parexel and Palantir Technologies have announced a new multi-year strategic partnership to leverage artificial intelligence (AI), enhancing clinical trial delivery for Parexel’s customers. Parexel will use Palantir’s Foundry and Artificial Intelligence Platform (AIP) to further power its clinical data platform.1

This new collaboration will add to the capabilities of Parexel’s Precision Pathway, an end-to-end operational approach which prioritizes the use of clean data in clinical trials. Supported by Palantir’s software, this approach will utilize an integrated digital environment to hyper-automate manual processes, safely promote data discoverability, distill insights from historical trials, and streamline coordination among scientific and operational teams and their partners.

"We're thrilled to expand our collaboration with Palantir—a leader in artificial intelligence technology—as we build on our application of AI to further improve clinical trial execution and advance our offerings in real-world evidence, advanced analytics, and health outcomes,” Jonathan Shough, chief information officer at Parexel said in a press release. “Leveraging our internal Parexel expertise and our strategic partnership with Palantir, we have novel solutions already in use or in various stages of development that demonstrate our commitment to be a fully digital CRO.”

With Foundry and AIP technology, Parexel’s customers will have access to high-quality, validated data, ensuring transparency during studies and condensed timelines from planning to submission.

“Parexel is well positioned to rapidly scale our use of AI to enhance data quality and streamline the clinical trial process to better deliver for our customers and patients,” said Stephen Pyke, DIC, chief clinical data and digital officer at Parexel and chair of the Association of Clinical Research Organization’s (ACRO) AI/ML committee said in the press release. “Combining our end-to-end delivery model with Palantir’s world-class security, governance, and Artificial Intelligence Platform will generate strategic insights to inform drug development and accelerate time to market.”

Pyke recently spoke with Applied Clinical Trials in a video interview series about the use of AI in clinical trials. He touched on the role of industry collaboration in advancing AI, benefits patients will see, and more.

“Parexel has embraced the principles of digital transformation using generative AI at remarkable speed and scale,” Lalarukh Haris Shaikh, PhD, executive, life sciences at Palantir said in the press release. “The company will significantly accelerate its business by untapping the value of data via an ontology constructed within Palantir Foundry and connecting it to the immense power of generative AI in AIP. We are delighted to deepen our exceptional collaboration with Parexel, empowering them to fully leverage the capabilities of AIP and Foundry throughout their clinical processes and business operations.”


1. Parexel and Palantir Expand Collaboration to Accelerate Clinical Data Delivery and Power Clinical Outcomes for Patients. News release. April 29, 2024. Accessed April 29, 2024.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.